Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 486

1.

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L.

Ann Intern Med. 2009 Feb 17;150(4):243-54.

PMID:
19221376
2.

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.

PMID:
10819699
3.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

5.

Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.

Odden MC, Pletcher MJ, Coxson PG, Thekkethala D, Guzman D, Heller D, Goldman L, Bibbins-Domingo K.

Ann Intern Med. 2015 Apr 21;162(8):533-41. doi: 10.7326/M14-1430.

6.

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.

PMID:
16520473
8.

Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.

Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K.

Circulation. 2017 Sep 19;136(12):1087-1098. doi: 10.1161/CIRCULATIONAHA.117.027067. Epub 2017 Jul 7.

PMID:
28687710
9.

Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.

de Vries FM, Denig P, Visser ST, Hak E, Postma MJ.

Value Health. 2014 Mar;17(2):223-30. doi: 10.1016/j.jval.2013.12.010.

10.
11.

Optimizing statin treatment for primary prevention of coronary artery disease.

Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S.

Ann Intern Med. 2010 Jan 19;152(2):69-77. doi: 10.7326/0003-4819-152-2-201001190-00004. Erratum in: Ann Intern Med. 2011 Jun 21;154(12):848.

PMID:
20083825
12.

Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.

Lim SS, Vos T, Peeters A, Liew D, McNeil JJ.

Med J Aust. 2001 Nov 5;175(9):459-64.

PMID:
11758073
13.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
14.

Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.

Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH.

Diabetes Care. 2003 Jun;26(6):1796-801.

PMID:
12766112
15.

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

Greving JP, Visseren FL, de Wit GA, Algra A.

BMJ. 2011 Mar 30;342:d1672. doi: 10.1136/bmj.d1672.

PMID:
21450800
16.

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.

Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J.

Health Technol Assess. 2008 May;12(21):iii, xi-xiii, 1-212. Review.

17.

Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model-Argentina.

Konfino J, Fernandez A, Penko J, Mason A, Martinez E, Coxson P, Heller D, Moran A, Bibbins-Domingo K, Pérez-Stable EJ, Mejía R.

J Gen Intern Med. 2017 May;32(5):524-533. doi: 10.1007/s11606-016-3907-8. Epub 2016 Nov 16.

18.
19.

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.

Ganz DA, Kuntz KM, Jacobson GA, Avorn J.

Ann Intern Med. 2000 May 16;132(10):780-7. Erratum in: Ann Intern Med 2002 Apr 16;136(8):635.

PMID:
10819700
20.

Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.

Davies GM, Vyas A, Baxter CA.

J Med Econ. 2017 Jul;20(7):723-731. doi: 10.1080/13696998.2017.1320559. Epub 2017 May 15.

PMID:
28426345

Supplemental Content

Support Center